Fig. 2From: Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian studyProportion of patients in clinical remission from weeks 8 to week 56 according to the NRI, LOCF and as-observed analysis. NRI nonresponder imputation, LOCF last observation carried forwardBack to article page